

Clovis Oncology, Inc.  
Form 4  
November 21, 2011

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**VITULLO NICOLE**

(Last) (First) (Middle)

**C/O DOMAIN ASSOCIATES,  
LLC, ONE PALMER SQUARE**

(Street)

**PRINCETON, NJ 08542**

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading  
Symbol  
**Clovis Oncology, Inc. [CLVS]**

3. Date of Earliest Transaction  
(Month/Day/Year)  
**11/21/2011**

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

\_\_\_\_ Director \_\_\_\_X\_\_\_\_ 10% Owner  
\_\_\_\_ Officer (give title below) \_\_\_\_ Other (specify below)

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
\_X\_ Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/21/2011		C		409,192	A	<u>(1)</u>	409,192	I	By Domain Partners VII, L.P. <u>(3)</u>
Common Stock	11/21/2011		C		409,192	A	<u>(1)</u>	818,384	I	By Domain Partners VII, L.P. <u>(3)</u>
Common Stock	11/21/2011		C		885,696	A	<u>(1)</u>	1,704,080	I	By Domain Partners VII, L.P. <u>(3)</u>
Common Stock	11/21/2011		C		370,799	A	<u>(2)</u>	2,074,879	I	By Domain Partners

Edgar Filing: Clovis Oncology, Inc. - Form 4

Common Stock	11/21/2011	P	916,058	A	\$ 13	2,990,937	I	VII, L.P. <sup>(3)</sup> By Domain Partners VII, L.P. <sup>(3)</sup>
Common Stock	11/21/2011	C	6,979	A	<u>(1)</u>	6,979	I	By DP VII Associates, L.P. <sup>(3)</sup>
Common Stock	11/21/2011	C	6,979	A	<u>(1)</u>	13,958	I	By DP VII Associates, L.P. <sup>(3)</sup>
Common Stock	11/21/2011	C	15,106	A	<u>(1)</u>	29,064	I	By DP VII Associates, L.P. <sup>(3)</sup>
Common Stock	11/21/2011	C	6,324	A	<u>(2)</u>	35,388	I	By DP VII Associates, L.P. <sup>(3)</sup>
Common Stock	11/21/2011	P	15,625	A	\$ 13	51,013	I	By DP VII Associates, L.P. <sup>(3)</sup>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount Number Shares
Series A-1 Preferred Stock	<u>(1)</u>	11/21/2011		C	1,186,657	<u>(1)</u> <u>(1)</u>	Common Stock 409,19
Series A-2 Preferred Stock	<u>(1)</u>	11/21/2011		C	1,186,657	<u>(1)</u> <u>(1)</u>	Common Stock 409,19
Series B Preferred Stock	<u>(1)</u>	11/21/2011		C	2,568,521	<u>(1)</u> <u>(1)</u>	Common Stock 885,69

# Edgar Filing: Clovis Oncology, Inc. - Form 4

Convertible Promissory Note	(2)	11/21/2011	C	\$ 4,703,771	(2)	(2)	Common Stock	370,792
Series A-1 Preferred Stock	(1)	11/21/2011	C	20,240	(1)	(1)	Common Stock	6,979
Series A-2 Preferred Stock	(1)	11/21/2011	C	20,240	(1)	(1)	Common Stock	6,979
Series B Preferred Stock	(1)	11/21/2011	C	43,809	(1)	(1)	Common Stock	15,100
Convertible Promissory Note	(2)	11/21/2011	C	\$ 80,229	(2)	(2)	Common Stock	6,324

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
VITULLO NICOLE C/O DOMAIN ASSOCIATES, LLC ONE PALMER SQUARE PRINCETON, NJ 08542			X	

## Signatures

/s/Kathleen K. Schoemaker,  
Attorney-in-Fact

11/21/2011

Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) All outstanding shares of the Issuer's preferred stock were automatically converted into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration.
- (2) The Convertible Promissory Note, plus interest accrued thereon through the closing of the IPO, automatically converted into Common Stock upon the closing of the IPO, based on the IPO price of \$13.00 per share.
- (3) The Reporting Person also indirectly beneficially owns 32,758 shares of Common Stock held by Domain Associates, LLC. The Reporting Person is a Managing Member of One Palmer Square Associates VII, LLC, which is the sole general partner of Domain Partners VII, L.P. and DP VII Associates, L.P. and Domain Associates, LLC. Pursuant to Instruction (4)(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities beneficially owned by each such entity. The Reporting Person disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.